[go: up one dir, main page]

NO982732L - Ny fremgangsmÕte - Google Patents

Ny fremgangsmÕte

Info

Publication number
NO982732L
NO982732L NO982732A NO982732A NO982732L NO 982732 L NO982732 L NO 982732L NO 982732 A NO982732 A NO 982732A NO 982732 A NO982732 A NO 982732A NO 982732 L NO982732 L NO 982732L
Authority
NO
Norway
Prior art keywords
insulin
new procedure
cgrp
niddm
amylin
Prior art date
Application number
NO982732A
Other languages
English (en)
Other versions
NO982732D0 (no
Inventor
Uffe Bang Olsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO982732D0 publication Critical patent/NO982732D0/no
Publication of NO982732L publication Critical patent/NO982732L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Foreliggende oppfinnelse ved- rører anvendelsen av forbindelser med den generelle formel (I) til reduksjon av blodglukose og/eller inhibering av utskillelsen, omløpet eller effekten av insulinantagoni- serende peptider som CGRP eller amylin. Forbindelsen kan således anvendes ved behandling av insulinresistens relatert til NIDDM (ikke-insulinavhengig diabe- tes mellitus) eller aldring.
NO982732A 1995-12-15 1998-06-12 Ny fremgangsmÕte NO982732L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK142695 1995-12-15
PCT/DK1996/000524 WO1997022338A1 (en) 1995-12-15 1996-12-12 Novel method

Publications (2)

Publication Number Publication Date
NO982732D0 NO982732D0 (no) 1998-06-12
NO982732L true NO982732L (no) 1998-08-14

Family

ID=8104711

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982732A NO982732L (no) 1995-12-15 1998-06-12 Ny fremgangsmÕte

Country Status (15)

Country Link
US (1) US5741791A (no)
EP (1) EP0869777A1 (no)
JP (1) JP3048067B2 (no)
KR (1) KR20000064411A (no)
AR (1) AR005075A1 (no)
AU (1) AU704825B2 (no)
BR (1) BR9612005A (no)
CA (1) CA2239487A1 (no)
CZ (1) CZ179598A3 (no)
HU (1) HUP9901652A3 (no)
IL (1) IL124557A0 (no)
NO (1) NO982732L (no)
PL (1) PL327445A1 (no)
WO (1) WO1997022338A1 (no)
ZA (1) ZA9610543B (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110913A (en) * 1994-01-04 2000-08-29 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
US7167748B2 (en) 1996-01-08 2007-01-23 Impulse Dynamics Nv Electrical muscle controller
US9289618B1 (en) 1996-01-08 2016-03-22 Impulse Dynamics Nv Electrical muscle controller
US8825152B2 (en) 1996-01-08 2014-09-02 Impulse Dynamics, N.V. Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue
US8321013B2 (en) * 1996-01-08 2012-11-27 Impulse Dynamics, N.V. Electrical muscle controller and pacing with hemodynamic enhancement
JP4175662B2 (ja) 1996-01-08 2008-11-05 インパルス ダイナミクス エヌ．ヴイ． 電気的筋肉制御装置
US9713723B2 (en) 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
ZA978792B (en) * 1996-10-04 1998-04-06 Novo Nordisk As N-substituted azaheterocyclic compounds.
US7006871B1 (en) 1997-07-16 2006-02-28 Metacure N.V. Blood glucose level control
US6207682B1 (en) 1998-12-22 2001-03-27 Novo Nordisk A/S Modified release formulations containing (R)-1-(10,11-dihydro-5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1propyl)-3-piperidinecarboxylic acid
WO2000037081A1 (en) * 1998-12-22 2000-06-29 Novo Nordisk A/S Novel formulation
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US8019421B2 (en) * 1999-03-05 2011-09-13 Metacure Limited Blood glucose level control
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8346363B2 (en) 1999-03-05 2013-01-01 Metacure Limited Blood glucose level control
US8700161B2 (en) 1999-03-05 2014-04-15 Metacure Limited Blood glucose level control
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6800618B2 (en) * 2001-05-07 2004-10-05 The United States Of America As Represented By The Secretary Of The Army Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof
WO2002089810A1 (en) * 2001-05-07 2002-11-14 United States Army Medical Research And Materiel Command Chemosensitizing agents against chloroquine resistant plasmodium falciparum and methods of making and using thereof
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
KR101001092B1 (ko) * 2001-11-21 2010-12-14 교와 학꼬 고교 가부시키가이샤 케모카인 수용체 길항제 및 이의 사용 방법
US7840262B2 (en) * 2003-03-10 2010-11-23 Impulse Dynamics Nv Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue
US11439815B2 (en) 2003-03-10 2022-09-13 Impulse Dynamics Nv Protein activity modification
WO2004112705A2 (en) * 2003-06-16 2004-12-29 Hypnion, Inc. Methods for treating sleep disorders
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US11779768B2 (en) 2004-03-10 2023-10-10 Impulse Dynamics Nv Protein activity modification
US8352031B2 (en) 2004-03-10 2013-01-08 Impulse Dynamics Nv Protein activity modification
WO2006119467A2 (en) 2005-05-04 2006-11-09 Impulse Dynamics Nv Protein activity modification
DE202004009224U1 (de) * 2004-06-14 2004-08-12 Isra Vision Systems Ag Sensor zur Vermessung der Oberfläche eines Objekts
CA2594673A1 (en) * 2004-12-09 2006-07-13 Impulse Dynamics Nv Protein activity modification
WO2006097934A2 (en) 2005-03-18 2006-09-21 Metacure Limited Pancreas lead
ATE484506T1 (de) * 2006-12-11 2010-10-15 Merck Sharp & Dohme Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren
CN101687886B (zh) * 2007-05-29 2012-11-07 中国科学院上海药物研究所 七元环化合物及其在防治糖尿病及代谢综合征中的药学用途
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
JP2020526592A (ja) 2017-07-13 2020-08-31 トニックス ファーマシューティカルズ ホールディング コーポレーション シクロベンザプリン類似体及びアミトリプチレン類似体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE560750A (no) * 1957-07-26
CA2091566A1 (en) * 1990-10-15 1992-04-16 Banavara L. Mylari Pyrrolidine dione derivatives
WO1992016226A1 (en) * 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds

Also Published As

Publication number Publication date
NO982732D0 (no) 1998-06-12
CZ179598A3 (cs) 1998-09-16
US5741791A (en) 1998-04-21
JP3048067B2 (ja) 2000-06-05
IL124557A0 (en) 1998-12-06
HUP9901652A2 (hu) 1999-09-28
AU1138497A (en) 1997-07-14
EP0869777A1 (en) 1998-10-14
PL327445A1 (en) 1998-12-07
HUP9901652A3 (en) 2000-04-28
JPH11507947A (ja) 1999-07-13
AU704825B2 (en) 1999-05-06
ZA9610543B (en) 1998-01-08
BR9612005A (pt) 1999-02-09
WO1997022338A1 (en) 1997-06-26
AR005075A1 (es) 1999-04-07
MX9804749A (es) 1998-10-31
CA2239487A1 (en) 1997-06-26
KR20000064411A (ko) 2000-11-06

Similar Documents

Publication Publication Date Title
NO982732L (no) Ny fremgangsmÕte
DE69432751D1 (de) Präparation und stabilisation von zellen
YU18799A (sh) Monociklični l-nukleozidi, njihovi analozi i njihova upotreba
ATE245416T1 (de) Neue fettanaloge zur behandlung von diabetes
WO2001052847A8 (en) Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging
NO940261L (no) 5-leddete heterocykler, fremgangsmåte ved fremstilling derav og legemidler som inneholder disse forbindelser
TR200101539T2 (tr) Serum glukoz ve trigliserid seviyelerini düşürme yöntemleri.
DE69231644D1 (de) Verwendung von makrolid-verbindungen gegen augenerkrankungen
ATE161835T1 (de) Benzoylbenzofuranderivate zur behandlung von herzarrhythmia
BG102619A (en) Substituted n-[(aminoiminomethyl or aminomethyl) phenyl] propylamides
DE69735442D1 (de) Antidiabetische mittel
ATE259644T1 (de) Behandlung von hämoglobin enthaltenden erythrozyten mit stickstoffoxyd
ATE70450T1 (de) Zusammensetzungen aus vanadium und peroxyd als nachahmungsmittel von insulin.
NO864241D0 (no) Fremgangsmaate ved bleking av cellulosemasse eller fraksjon derav, anlegg til bruk ved gjennomfoeringen av fremgangsmaaten og skruepresse, saerlig til bruk ved fremgangsmaaten henholdsvis i anlegget.
GR852979B (no)
KR960028911A (ko) 누에분말을 유효성분으로 포함하는 혈당강하제 및 그의 제조방법
CA2334864A1 (en) A reference compound for use in the analysis of levosimendan batches
NO20061085L (no) Kombinasjonsterapi for glykemisk kontroll
ATE237683T1 (de) Protein p140 und dafür kodierende dns
RU94044362A (ru) Способ обесцвечивания кератиновых волокон
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
IE821049L (en) Aminocyclitol derivatives
ES2082212T3 (es) Nuevos inhibidores de alfa-glucosidasa.
EP0145361A3 (en) Acetylene derivatives for the treatment of hypertension and angina
WO2000054760A3 (en) Bicyclo (3.3.1) nonenes useful for the treatment of diabetes and hypertriglyceridemia

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application